Holen Sie sich die Stockscreener-App
11.76
2.50%
-0.255
Schlusskurs vom Vortag:
$12.01
Offen:
$13.65
24-Stunden-Volumen:
92,527
Relative Volume:
1.19
Marktkapitalisierung:
$355.64M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-9.2559
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+1.21%
1M Leistung:
+1.74%
6M Leistung:
+70.45%
1J Leistung:
-5.57%
1-Tages-Spanne:
$11.18
$13.65
1-Wochen-Bereich:
$11.18
$13.65
52-Wochen-Spanne:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
11.75 | 355.64M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
113.24 | 196.55B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.11 | 141.03B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
366.48 | 139.65B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
81.52 | 104.60B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.43 | 43.28B | 6.60B | 4.16B | 490.10M | 6.93 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Inc (NPCE): A New Perspective - Stocks Register
NeuroPace Shares Updates on Financial Performance and Board of Directors - Defense World
NeuroPace reports preliminary Q4 revenue - MSN
NeuroPace Sees Rise in 4Q, Full-Year Sales - MarketWatch
NeuroPace Strengthens Board and Reports Strong 2024 Results - TipRanks
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates - The Manila Times
NeuroPace narrows FY24 revenue view to $79.4M-$79.9M from $78M-$80M - TipRanks
Neuropace, Inc. Appoints Scott Huennekens to Its Board of Directors - Marketscreener.com
NeuroPace Inc (NPCE) Trading Down 5.31% on Jan 8 - GuruFocus.com
Institutions profited after NeuroPace, Inc.'s (NASDAQ:NPCE) market cap rose US$37m last week but private equity firms profited the most - Simply Wall St
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $2.21 Million Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
When the Price of (NPCE) Talks, People Listen - Stock Traders Daily
Head to Head Analysis: Minerva Surgical (NASDAQ:UTRS) & NeuroPace (NASDAQ:NPCE) - Defense World
State Street Corp Increases Stock Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) versus NEXGEL (NASDAQ:NXGL) Head to Head Contrast - Defense World
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $14.50 - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Average PT from Analysts - MarketBeat
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Nasdaq
NeuroPace to Present at J.P. Morgan's Prestigious Healthcare Conference in January 2025 - StockTitan
NeuroPace (NASDAQ:NPCE) Trading Up 4% – Should You Buy? - Defense World
NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00 - MarketBeat
JPMorgan sees NeuroPace stock undervalued, highlights clinically superior RNS device - Investing.com
NeuroPace (NASDAQ:NPCE) Trading Up 4%Should You Buy? - MarketBeat
NeuroPace's SWOT analysis: epilepsy treatment innovator's stock poised for growth - Investing.com
Perspective Therapeutics (NYSE:CATX) vs. NeuroPace (NASDAQ:NPCE) Head to Head Contrast - Defense World
Neurostimulation Market is experiencing new opportunities & - openPR
NPCENeuropace, Inc. Latest Stock News & Market Updates - StockTitan
NeuroPace to Host Investor Day on January 28th in New York City - The Manila Times
NeuroPace, Inc. Announces Investor Day to Discuss RNS Technology and Future Plans on January 28, 2025 - Nasdaq
NeuroPace Sets Investor Day to Showcase RNS Technology and Growth Strategy in Epilepsy Treatment - StockTitan
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet - MSN
How To Trade (NPCE) - Stock Traders Daily
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting - The Manila Times
NeuroPace's RNS System Shows 82% Seizure Reduction, Featured in 70+ Studies at AES 2024 - StockTitan
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar - Simply Wall St
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome - The Manila Times
NeuroPace Completes Groundbreaking Trial Enrollment for Severe Epilepsy Treatment Innovation - StockTitan
NeuroPace Inc (NPCE) Stock Price Up 7.36% on Dec 2 - GuruFocus.com
NeuroPace Inc (NPCE) Shares Up 3.41% on Nov 29 - GuruFocus.com
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $14.60 - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News
NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
What Makes NeuroPace (NPCE) a New Buy Stock - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Oct 23 '24 |
Sale |
6.02 |
147 |
885 |
5,494,836 |
2.70%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):